Fujita and coworkers, utilizing 11C-(R)-rolipram positron emission tomography, demonstrate
that human subjects with major depression exhibit reductions in the enzyme phosphodiesterase-4
(PDE4) in a number of brain regions (
1
). PDE4, a cyclic adenosine monophosphate (AMP) phosphodiesterase, is an important
regulator of cyclic AMP concentrations in the brain; it has been suggested as a molecular
target for antidepressant drug discovery (
2
). The present study provides support for this premise and also suggests that global
reductions in cyclic AMP signaling in the brain may be associated with major depression.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Downregulation of brain phosphodiesterase type IV measured with11C-(R)-rolipram positron emission tomography in major depressive disorder.Biol Psychiatry. 2012; 72: 548-554
- Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).Trends Pharmacol Sci. 2004; 25: 158-163
- Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.Nat Biotechnol. 2010; 28: 63-70
- Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.J Neurosci. 2011; 31: 172-183
- Synaptic plasticity and mood disorders.Mol Psychiatry. 2002; 7: S29-S34
- [(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims.Am J Psychiatry. 2002; 159: 66-73
- Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.Mol Pharmacol. 1996; 50: 891-899
- Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function.J Pharmacol Exp Ther. 2003; 307: 246-253
- Altered axonal targeting and short-term plasticity in the hippocampus of Disc1 mutant mice.Proc Natl Acad Sci USA. 2011; 108: E1349-E1358
- PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.Biochem J. 2003; 370: 1-18
Article info
Publication history
Accepted:
July 17,
2012
Received:
July 16,
2012
Identification
Copyright
© 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive DisorderBiological PsychiatryVol. 72Issue 7
- PreviewPhosphodiesterase type IV (PDE4), an important component of the cyclic adenosine monophosphate (cAMP) cascade, selectively metabolizes cAMP in the brain to the inactive monophosphate. Basic studies suggest that PDE4 mediates the effects of several antidepressants. This study sought to quantify the binding of 11C-(R)-rolipram, a PDE4 inhibitor, as an indirect measure of this enzyme's activity in the brain of individuals with major depressive disorder (MDD) compared with healthy control subjects.
- Full-Text
- Preview
